Support Care Cancer (2015) 23:2841 DOI 10.1007/s00520-015-2842-2


Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study Yolanda Escobar 1 & Gerardo Cajaraville 2 & Juan Antonio Virizuela 3 & Rosa Álvarez 1 & Andrés Muñoz 1 & Olatz Olariaga 2 & María José Tamés 2 & Begoña Muros 4 & María Jose Lecumberri 5 & Jaime Feliu 6 & Purificación Martínez 7 & Juan Carlos Adansa 8 & María José Martínez 9 & Rafael López 10 & Ana Blasco 11 & Pere Gascón 12 & Virginia Calvo 13 & Pablo Luna 14 & Joaquín Montalar 15 & Patricia Del Barrio 16 & María Victoria Tornamira 16

Published online: 14 July 2015 # Springer-Verlag Berlin Heidelberg 2015

Erratum to: Support Care Cancer DOI 10.1007/s00520-015-2809-3 The original version of this paper unfortunately contained error. The name of Isabel Camacho was incorrectly included as author of this article and is now eliminated in the author group as well as corresponding author of this article.

The online version of the original article can be found at 10.1007/s00520-015-2809-3. * María Victoria Tornamira [email protected] 1

Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, 28007 Madrid, Spain


Servicio de Farmacia, Onkologikoa, Paseo Doctor Begiristain, 121, Donostia-San Sebastián 20014, Gipuzkoa, Spain


Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Avenida Dr Fedriani, 3, 41009 Seville, Spain


Servicio de Farmacia, Hospital Clínico Virgen de la Victoria de Málaga, Campus de Teatinos s/n, 29010 Málaga, Spain


Servicio de Oncología Médica, Hospital de Navarra, Calle Irunlarrea, 3, 31008 Pamplona, Spain


Servicio de Oncología. Médica de día de Oncología, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid, Spain


Servicio de Oncología Médica, Hospital Universitario de Basurto, Avenida de Montevideo, 18, 48013 Bilbao, Spain


Servicio de Oncología, Complejo Asistencial de Salamanca, Paseo de San Vicente, 58-182, 37007 Salamanca, Spain


Servicio de Farmacia Hospitalaria, Hospital Universitario Puerta del Mar, Avenida Ana de Viya, 21, 11009 Cádiz, Spain


Servicio de Oncología Médica, Complejo Hospitalario Universitario de Santiago, Travesía de Choupana, s/n 15706, Santiago de Compostela, Spain


Servicio Oncología Hospitalaria, Hospital General Universitario de Valencia, Avenida de las Tres Cruces, 2, 46014 Valencia, Spain


Servicio de Oncología Médica, Hospital Clinic de Barcelona, Calle Villarroel 170, Barcelona, Spain


Servicio de Oncología Médica, Hospital Puerta del Hierro, Calle Manuel de Falla, 1, 28222 Majadahonda, Madrid, Spain


Servicio de Oncología Médica, Hospital Universitario Sons Espases, Carretera Valldemossa, 79, 07010 Palma, Mallorca, Spain


Servicio de Oncología Médica, Hospital Universitario y Politécnico La Fe, Bulevar Sur, s/n, 46026 Valencia, Spain


Merck Sharp & Dohme, Calle Josefa Valcárcel, 38, 28027 Madrid, Spain

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.

Erratum to: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. - PDF Download Free
175KB Sizes 0 Downloads 7 Views

Recommend Documents

Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.
Patients with gastrointestinal cancer who were receiving moderately emetogenic chemotherapy (MEC) were switched from granisetron, a first-generation 5-hydroxytryptamine-3 receptor antagonist, to palonosetron at our hospital. In the present study, we

Chemotherapy-Induced Nausea and Vomiting.
Despite treatment advances, nausea and vomiting, especially anticipatory nausea and vomiting, delayed nausea and vomiting and nausea alone, are still the most common, expected and feared side effects among patients receiving chemotherapy. Of the 70 t

Anticipatory nausea and vomiting due to chemotherapy.
As a specific variation of chemotherapy-induced nausea and vomiting, anticipatory nausea and vomiting (ANV) appears particularly linked to psychological processes. The three predominant factors related to ANV are classical conditioning; demographic a

Treatment of Nausea and Vomiting During Chemotherapy.
Nausea and vomiting are two of the most troubling side effects patients experience during chemotherapy. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still a

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
To establish the role of antiemetic therapy with neurokinin-1 (NK1) receptor antagonists (RAs) in nonanthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.)

Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.
Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively controlled in the acute phase, it may still occur in the delayed phase. Identifying at-risk patients is complex and requires consideration of clinical, personal, demographic

Does previous chemotherapy-induced nausea and vomiting predict postoperative nausea and vomiting?
Postoperative nausea and vomiting (PONV) remains a problem in the postoperative period. Previous PONV in oncology patients has recently been associated with chemotherapy-induced nausea and vomiting (CINV). We assessed if CINV could improve Apfel's he

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.
Different antiemetic medications with or without aprepitant are recommended for moderately emetic-risk chemotherapy (MEC) depending on the emetic potential of chemotherapy agents, although the criterion for the use of aprepitant is still unclear. The

Alternative Methods to Treat Nausea and Vomiting from Cancer Chemotherapy.
Chemotherapy Induced Nausea and Vomiting (CINV) is among the most intensive side effects and critical concerns for patients with cancer. Most of these patients experience nausea and vomiting after chemotherapy. Sometimes, this is so annoying that it